D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This study is based on the hypothesis that by increasing N-methyl-D-aspartic acid (NMDA)
receptor function in the brain and thereby increasing the capacity of the brain to both form
new connections and strengthen existing connections, schizophrenic patients may derive both
greater and sustained benefit from cognitive retraining.
Phase:
Phase 3
Details
Lead Sponsor:
Yale University
Collaborators:
Donaghue Medical Research Foundation National Alliance for Research on Schizophrenia and Depression